GSK has kicked off 2026 with a stronger-than-expected performance, beating market forecasts for its first-quarter earnings.
But this result is more than just good numbers; it's significant because the company has successfully navigated three major concerns that were weighing on investors' minds. These were potential U.S. trade policy risks, the performance of its key vaccines, and lingering legal uncertainties. Let's break down how GSK addressed each of these.
First and foremost was the threat of U.S. tariffs. The White House had announced a policy under Section 232 that could have imposed tariffs of up to 100% on certain pharmaceuticals. This was a major risk for GSK, as nearly half of its sales come from the U.S. market. However, the company proactively secured a definitive agreement with the U.S. government, granting it relief from these tariffs until early 2029. This single move removed a massive cloud of uncertainty and made its financial guidance for the year much more reliable.
Second, let's look at the vaccine story, which was a mix of good and not-so-good news. The star performer was Shingrix, the shingles vaccine, which saw impressive 20% growth, especially driven by strong demand outside the U.S. On the other hand, sales for the RSV vaccine, Arexvy, declined. This might seem worrying, but it was largely expected due to tougher comparisons with the previous year and more restrictive vaccination guidelines in 2025. The good news is that U.S. health authorities have since broadened the recommendations for RSV vaccines, which should help sales recover in the upcoming seasons.
Finally, the company has largely put its legal troubles behind it. The major settlements related to the Zantac litigation in late 2024 resolved the vast majority of cases. This cleared up financial uncertainty, allowing GSK to confidently continue its plans to return cash to shareholders through stable dividends and share buybacks.
By effectively managing these significant risks, GSK's solid Q1 performance isn't just a one-off success. It demonstrates resilience and provides a firm foundation for achieving its full-year financial targets.
- Section 232: A U.S. trade law that allows for tariffs to be imposed on imports if they are determined to threaten national security.
- Core EPS (Earnings Per Share): A measure of a company's profitability that excludes certain one-time or non-operational items to give a clearer view of underlying performance.
- CER (Constant Exchange Rate): A way of reporting financial performance that removes the effect of currency fluctuations, showing the true underlying growth of the business.